M. Schirru

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).

A. Drilon, S. Ou, A. Shaw, 2017, Cancer discovery.

TRKA expression and NTRK1 gene copy number across solid tumours

E. Valtorta, S. Veronese, A. Sartore-Bianchi, 2018, Journal of Clinical Pathology.

Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab

Maria Laura De Marchis, F. Guadagni, V. Formica, 2011, International Journal of Colorectal Disease.

Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility: A Single-Institution Experience

E. Valtorta, K. Bencardino, S. Veronese, 2017, Targeted Oncology.